Tag Archives: Adverse effect

Prozac aids stroke recovery

Giving stroke patients Prozac soon after the event could help their recovery from paralysis, a study has found.

Researchers discovered more improvement in movement and greater independence after three months in patients taking the antidepressant (also known as fluoxetine), compared to placebo.

The Lancet Neurology study was based on research on 118 patients in France.

UK stroke experts said the findings were “promising”.

This was the largest study of selective serotonin re-uptake inhibitors (SSRIs) and stroke recovery to date.

Prozac

Prozac

Tests on stroke patients 90 days after being given the drug found that patients taking fluoxetine had gained significantly more function in their upper and lower limbs than patients who were not given the drug.

Patients in the fluoxetine group were also more likely to be coping independently.

All patients in the study had moderate to severe motor disabilities following their stroke.

The study noted that the side-effects from the antidepressant were generally mild and infrequent, although this group did notice more instances of nausea and diarrhoea.


The authors, led by Professor François Chollet, said: “The positive effect of the drug on motor function of recovering patients suggests that the… action of SSRIs provides a new pathway that should be explored further in the treatment of acute ischaemic stroke.”

Every year in the UK 150,000 people have a stroke and a third of these will be left with a disability such as paralysis down one side of their body.

Dr Sharlin Ahmed, research liaison officer at the UK Stroke Association, said: “We are continually searching for new treatments which can improve the outcomes for stroke survivors and the results of this research look promising.

“Antidepressants, such as fluoxetine, can be used to treat stroke patients with depression which is a common side effect of stroke, so it’s very interesting to see that this already licensed drug could have a dual benefit.

“However, further research needs to be undertaken before the use of this antidepressant can be accepted as an effective treatment for improving movement following a stroke.”

Canada restricts Avandia

OTTAWA — Health Canada has announced new restrictions and a consent form for the diabetes medication rosiglitazone, sold under the brand name Avandia, because of an increased risk of heart-related illness.

The national drug regulator said Thursday that it changed the restrictions after reviewing recent data and in conjunction with manufacturer GlaxoSmithKline Inc.

The drug may increase the risk of serious heart problems, including heart failure, angina (chest pain), heart attack or fluid retention (with or without rapid weight gain). It should not be used by patients who have or have had heart problems, the agency said in a release Thursday.

Avandia

Avandia

Health Canada says the medication should be used only in patients with Type 2 diabetes when all other diabetes medicines taken orally have not lowered blood sugar enough, or are not appropriate.

The agency said that patients should not stop taking the medication until they have seen their physician to discuss their diabetes treatment, including other options and the benefits and risks of taking rosiglitazone.


Before starting or renewing a prescription for Avandia, doctors must now advise patients to read the consumer information for the drug and to read and sign a consent form indicating they understand the heart-related risks of the medication and they have discussed other treatment options.

The restrictions affect Avandia (rosiglitazone), Avandamet (contains both rosiglitazone and metformin) and Avandaryl (contains both rosiglitazone and glimepiride).

The informed consent form, Product Monographs and Consumer Information are available on GSK’s Canadian website, www.gsk.ca.

Any serious or unexpected adverse reactions in patients taking the medication should be reported to GlaxoSmithKline Inc. at 1-800-387-7374 or Health Canada at www.healthcanada.gc.ca/medeffect or toll-free at 1-866-234-2345.